default_top_notch
default_news_top
default_news_ad1
default_nd_ad1

Abbvie’s hepatitis C drug expands indication

Lee Han-soo  Published 2018.10.12  15:40  Updated 2018.10.12 15:40

공유
default_news_ad2

Abbvie’s Maviret, a hepatitis C treatment, has received approval for additional indications in treating liver and kidney transplant patients from the Ministry of Food and Drug Safety.

Under the updated approval, patients with liver or kidney transplants can now take the medication for 12 weeks after receiving an operation. It is also possible to use the treatment in combination with tacrolimus, one of the most commonly used immunosuppressants for transplant patients.

The ministry also allowed medical professionals to consider a 16 week treatment for genotype 1-infected patients who have received nonstructural protein 5A (NS5A) protease inhibitor treatment but have not received nonstructural protein 3/4A (NS3/4A) protease inhibitor treatment, and genotype 3-infected patients who have treatment experience with regimens containing (peg)interferon, ribavirin, and/or sofosbuvir.

Maviret is Korea’s first and only oral hepatitis C treatment which covers all genotypes from type 1 to 6. Also, the therapy is ribavirin-free when treating genotype-2 patients, who account for half of the nation’s hepatitis C patients.

corea022@docdocdoc.co.kr

<© KBR , All rights reserved.>
default_news_ad5
default_news_bottom
default_nd_ad4
default_bottom
#top
default_bottom_notch